Form 4: Pulmonx Director Glendon E. French III Sells 20,000 Shares Under 10b5-1 Trading Plan

Director Glendon E. French III of Pulmonx Corp sold 20,000 shares of common stock at an average price of $7.85, executed under a pre-arranged 10b5-1 trading plan.

Summary

• On March 20, 2025, Glendon E. French III, a director of Pulmonx Corp, sold 20,000 shares of common stock.
• The sale was executed under a Rule 10b5-1 trading plan adopted on June 10, 2024.
• The shares were sold at a weighted average price of $7.85, with individual prices ranging from $7.71 to $7.95.
• Following the transaction, French directly owns 991,974 shares of Pulmonx Corp.
• The reporting person will provide full information regarding the number of shares sold at each separate price within the range upon request.

Sentiment

Score: 5

Explanation: The document reports a routine stock sale by a director under a pre-arranged trading plan, indicating a neutral sentiment.

Industry Context

Sales by company insiders are a common occurrence and are often viewed in the context of the insider's personal financial planning. The use of a 10b5-1 trading plan suggests the sales were pre-planned and not based on current, non-public information.

Stakeholder Impact

• The sale of shares by a director could have a minor impact on shareholder sentiment, but the existence of a 10b5-1 plan mitigates concerns about insider trading.

Key Dates

Keywords

Pulmonx Corp, Glendon E. French III, Form 4, Stock Sale, 10b5-1 Trading Plan, Director, LUNG